Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Keros Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
KROS
Nasdaq
8731
https://www.kerostx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Keros Therapeutics Inc
Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 37%?
- Apr 15th, 2024 12:47 pm
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
- Mar 14th, 2024 12:00 pm
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
- Mar 5th, 2024 1:00 pm
Keros Therapeutics Inc (KROS) Reports Increased R&D Spending and Net Loss in 2023
- Feb 28th, 2024 9:42 pm
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
- Feb 28th, 2024 9:01 pm
Keros Therapeutics, Inc. (KROS) is on the Move, Here's Why the Trend Could be Sustainable
- Feb 28th, 2024 1:50 pm
Does Keros Therapeutics, Inc. (KROS) Have the Potential to Rally 35.66% as Wall Street Analysts Expect?
- Feb 21st, 2024 2:55 pm
Recent Price Trend in Keros Therapeutics, Inc. (KROS) is Your Friend, Here's Why
- Feb 12th, 2024 1:50 pm
Wall Street Analysts Predict a 45.35% Upside in Keros Therapeutics, Inc. (KROS): Here's What You Should Know
- Jan 31st, 2024 2:55 pm
Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress
- Jan 29th, 2024 1:00 pm
Keros Therapeutics, Inc. (NASDAQ:KROS) institutional owners may be pleased with recent gains after 2.4% loss over the past year
- Jan 25th, 2024 10:43 am
Keros Therapeutics, Inc. (KROS) Is a Great Choice for 'Trend' Investors, Here's Why
- Jan 24th, 2024 1:50 pm
Keros Therapeutics, Inc. (KROS) Just Flashed Golden Cross Signal: Do You Buy?
- Jan 23rd, 2024 2:55 pm
How Much Upside is Left in Keros Therapeutics, Inc. (KROS)? Wall Street Analysts Think 57.46%
- Jan 15th, 2024 2:55 pm
Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock
- Jan 9th, 2024 1:00 pm
Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
- Jan 4th, 2024 2:29 am
Keros Therapeutics Announces Proposed Public Offering of Common Stock
- Jan 3rd, 2024 9:05 pm
Keros Therapeutics to Develop KER-065 for the Treatment of Obesity
- Jan 3rd, 2024 1:00 pm
Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation
- Dec 11th, 2023 3:28 pm
Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition
- Dec 11th, 2023 11:00 am
Scroll